Driveline exit-site care protocols in patients with left ventricular assist devices: a systematic review

Zeliha Ozdemir Koken, Yunus C Yalcin, Diana van Netten, Chantal C de Bakker, Maaike van der Graaf, Umit Kervan, Nelianne J Verkaik, Kadir Caliskan, Zeliha Ozdemir Koken, Yunus C Yalcin, Diana van Netten, Chantal C de Bakker, Maaike van der Graaf, Umit Kervan, Nelianne J Verkaik, Kadir Caliskan

Abstract

Objectives: Driveline infections continue to be a significant complication following left ventricular assist device (LVAD) implantation. Driveline exit-site care is crucial for the prevention of infections; however, there are no uniform guidelines. The goal of this study was to provide an overview of the currently published driveline exit-site care protocols in patients with LVAD.

Methods: A systematic literature review was performed. Studies before 15 December 2020 were included if the number of driveline infections was a primary outcome and the driveline exit-site care protocol was explained.

Results: Eleven articles were included in the systematic review, including 1602 patients with LVADs. The median of the frequency of driveline infections in the articles was 13.8% with a range of 0-52.6%. There was a marked variability in the methods of care of driveline exit sites, without a standardized driveline dressing technique in patients with LVADs. The frequency of driveline infections was 6-7.5% in studies using a dressing kit that included chlorhexidine, a silver-based dressing and an anchoring device. Furthermore, there was variability in the anchoring devices and the frequency of dressing changes, which varied from daily to weekly. No specific anchoring device or change frequency was found to be superior.

Conclusions: Based on this systematic review, driveline exit care protocols that included chlorhexidine, a silver-based dressing, the use of an anchoring device and dressing kits might be best in reducing driveline infection rates. However, prospective studies with larger cohorts are needed to establish the optimal protocol for driveline exit-site care.

Keywords: Care; Dressing; Driveline; Driveline infection; Left ventricular assist device; Protocols.

© The Author(s) 2021. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery.

Figures

Figure 1:
Figure 1:
Flow diagram summarizing the review process.
Figure 2:
Figure 2:
Recommendations based on the systematic review.
https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8434872/bin/ezab195f3.jpg

References

    1. Kirklin JK, Pagani FD, Kormos RL, Stevenson LW, Blume ED, Myers SL. et al.Eighth annual INTERMACS report: special focus on framing the impact of adverse events. J Heart Lung Transplant 2017;36:1080–6.
    1. Hannan MM, Xie R, Cowger J, Schueler S, de By T, Dipchand AI. et al.Epidemiology of infection in mechanical circulatory support: a global analysis from the ISHLT Mechanically Assisted Circulatory Support Registry. J Heart Lung Transplant 2019;38:364–73.
    1. Goldstein DJ, Naftel D, Holman W, Bellumkonda L, Pamboukian SV, Pagani FD. et al.Continuous-flow devices and percutaneous site infections: clinical outcomes. J Heart Lung Transplant 2012;31:1151–7.
    1. Sharma V, Deo SV, Stulak JM, Durham LA 3rd, Daly RC, Park SJ. et al.Driveline infections in left ventricular assist devices: implications for destination therapy. Ann Thorac Surg 2012;94:1381–6.
    1. Hieda M, Sata M, Seguchi O, Yanase M, Murata Y, Sato T. et al.Importance of early appropriate intervention including antibiotics and wound care for device-related infection in patients with left ventricular assist device. Transplant Proc 2014;46:907–10.
    1. Wus L, Manning M, Entwistle JW 3rd. Left ventricular assist device driveline infection and the frequency of dressing change in hospitalized patients. Heart Lung 2015;44:225–9.
    1. Stahovich M, Sundareswaran KS, Fox S, Hallinan W, Blood P, Chen L. et al.Reduce driveline trauma through stabilization and exit site management: 30 days feasibility results from the multicenter RESIST study. ASAIO J 2016;62:240–5.
    1. Lander MM, Kunz N, Dunn E, Althouse AD, Lockard K, Shullo MA. et al.Substantial reduction in driveline infection rates with the modification of driveline dressing protocol. J Card Fail 2018;24:746–52.
    1. Wilcox JE, Cameron KA, Harap RS, Shanklin KL, Grady KL, Cohen ER. et al.Ventricular assist device driveline dressing-change protocols: a need for standardization. A report from the SimVAD Investigators. J Card Fail 2019;25:695–7.
    1. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Open Med 2009;3:e123–30.
    1. Schlöglhofer T, Michalovics P, Riebandt J, Angleitner P, Stoiber M, Laufer G. et al.Left ventricular assist device driveline infections in three contemporary devices. Artif Organs 2020:1–9. doi:10.1111/aor.13843.
    1. Aburjania N, Sherazi S, Tchantchaleishvili V, Alexis JD, Hay CM.. Stopping conventional showering decreases Pseudomonas infections in left ventricular assist device patients. Int J Artif Organs 2017;40:282–5.
    1. Durand ML, Ennis SC, Baker JN, Camuso JM, McEachern KM, Kotton CN. et al.Topical polymyxin-trimethoprim prophylaxis may decrease the incidence of driveline infections in patients with continuous-flow left ventricular assist devices. Artif Organs 2017;41:169–75.
    1. Cagliostro B, Levin AP, Fried J, Stewart S, Parkis G, Mody KP. et al.Continuous-flow left ventricular assist devices and usefulness of a standardized strategy to reduce drive-line infections. J Heart Lung Transplant 2016;35:108–14.
    1. Son AY, Stein LH, DeAnda A, Katz SD, Smith DE, Reyentovich A. et al.Impact of chlorhexidine gluconate intolerance on driveline infection during chronic HeartMate II left ventricular assist device support. Int J Artif Organs 2017;39:570–4.
    1. Menon AK, Baranski SK, Unterkofler J, Autschbach R, Moza AK, Goetzenich A. et al.Special treatment and wound care of the driveline exit site after left ventricular assist device implantation. Thorac Cardiovasc Surg 2015;63:670–4.
    1. Stulak JM, Maltais S, Cowger J, Joyce LD, Daly RC, Park SJ. et al.Prevention of percutaneous driveline infection after left ventricular assist device implantation: prophylactic antibiotics are not necessary. ASAIO J 2013;59:570–4.
    1. Hozayen SM, Soliman AM, Eckman PM.. Comparison of two ventricular assist device dressing change protocols. J Heart Lung Transplant 2012;31:108–9.
    1. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007;370:1453–7.
    1. Edmiston CE Jr, Bruden B, Rucinski MC, Henen C, Graham MB, Lewis BL.. Reducing the risk of surgical site infections: does chlorhexidine gluconate provide a risk reduction benefit? Am J Infect Control 2013;41:S49–55.
    1. Milstone AM, Passaretti CL, Perl TM.. Chlorhexidine: expanding the armamentarium for infection control and prevention. Clin Infect Dis 2008;46:274–81.
    1. Bigliardi PL, Alsagoff SAL, El-Kafrawi HY, Pyon JK, Wa CTC, Villa MA.. Povidone iodine in wound healing: a review of current concepts and practices. Int J Surg 2017;44:260–8.
    1. Lee I, Agarwal RK, Lee BY, Fishman NO, Umscheid CA.. Systematic review and cost analysis comparing use of chlorhexidine with use of iodine for preoperative skin antisepsis to prevent surgical site infection. Infect Control Hosp Epidemiol 2010;31:1219–29.
    1. Darouiche RO, Wall MJ Jr, Itani KM, Otterson MF, Webb AL, Carrick MM. et al.Chlorhexidine-alcohol versus povidone-iodine for surgical-site antisepsis. N Engl J Med 2010;362:18–26.
    1. European Environmental Bureau Zero Mercury Working Group. Mercury in Products. 2019. (15 December 2020, date last accessed).
    1. Hubner NO, Siebert J, Kramer A.. Octenidine dihydrochloride, a modern antiseptic for skin, mucous membranes and wounds. Skin Pharmacol Physiol 2010;23:244–58.
    1. Koburger T, Hubner NO, Braun M, Siebert J, Kramer A.. Standardized comparison of antiseptic efficacy of triclosan, PVP-iodine, octenidine dihydrochloride, polyhexanide and chlorhexidine digluconate. J Antimicrob Chemother 2010;65:1712–19.
    1. Dhivya S, Padma VV, Santhini E.. Wound dressings—a review. Biomedicine (Taipei) 2015;5:22.
    1. Sibbald RG, Contreras-Ruiz J, Coutts P, Fierheller M, Rothman A, Woo K.. Bacteriology, inflammation, and healing: a study of nanocrystalline silver dressings in chronic venous leg ulcers. Adv Skin Wound Care 2007;20:549–58.
    1. Leaper overview of the evidence on the efficacy of silver dressings. J Wound Care 2011;20:8–14.
    1. Storm-Versloot MN, Vos CG, Ubbink DT, Vermeulen H.. Topical silver for preventing wound infection. Cochrane Database Syst Rev 2010;CD006478. doi:10.1002/14651858.CD006478.pub2.
    1. Michaels JA, Campbell B, King B, Palfreyman SJ, Shackley P, Stevenson M.. Randomized controlled trial and cost-effectiveness analysis of silver-donating antimicrobial dressings for venous leg ulcers (VULCAN trial). Br J Surg 2009;96:1147–56.
    1. Lee SM, Park IK, Kim YS, Kim HJ, Moon H, Mueller S. et al.Superior absorption and retention properties of foam-film silver dressing versus other commercially available silver dressing. Biomater Res 2016;20:22.
    1. Kusne S, Mooney M, Danziger-Isakov L, Kaan A, Lund LH, Lyster H. et ISHLT consensus document for prevention and management strategies for mechanical circulatory support infection. J Heart Lung Transplant 2017;36:1137–53.
    1. Potapov EV, Antonides C, Crespo-Leiro MG, Combes A, Farber G, Hannan MM. et al.2019 EACTS Expert Consensus on long-term mechanical circulatory support. Eur J Cardiothorac Surg 2019;56:230–70.
    1. Bernhardt AM, Schloglhofer T, Lauenroth V, Mueller F, Mueller M, Schoede A. et al.; Driveline Expert STagINg and carE DESTINE Study Group, a Ventricular Assist Device Driveline Infection Study Group. Prevention and early treatment of driveline infections in ventricular assist device patients—the DESTINE staging proposal and the first standard of care protocol. J Crit Care 2020;56:106–12.
    1. Baronetto A, Centofanti P, Attisani M, Ricci D, Mussa B, Devotini R. et al.A simple device to secure ventricular assist device driveline and prevent exit-site infection. Interact CardioVasc Thorac Surg 2014;18:415–17.
    1. Schloglhofer T, Robson D, Bancroft J, Sorensen G, Kaufmann F, Sweet L. et al.International coordinator survey results on the outpatient management of patients with the HeartWare(R) ventricular assist system. Int J Artif Organs 2017;39:553–7.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera